Xiaomi Shares Jump on Europe EV Expansion Plan 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Milei Threatens Falkland Oil Firms With Sanctions 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Add as a preferred source on Google
TEMPLE CITY, Calif., Feb. 23, 2018 -- Fulgent Genetics, Inc. (NASDAQ:FLGT) (“Fulgent Genetics” or the “company”) today announced that its Chairman and Chief Executive Officer Ming Hsieh and its Chief Financial Officer Paul Kim are scheduled to participate in the 2018 BTIG Healthcare Conference on February 28, 2018 and March 1, 2018 in Snowbird, Utah.
At the conference, these representatives of the company will participate in a series of one-on-one meetings, which will not be webcast.
About Fulgent Genetics
Fulgent Genetics is a growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the quality of patient care. The company has developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. This platform allows the company to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. The company believes its current test menu, which includes approximately 18,000 single-gene tests and more than 850 pre-established, multi-gene, disease-specific panels, offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results.
Investor Relations Contacts:
The Blueshirt Group
Nicole Borsje, 415-217-2633, [email protected]
